SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001104659-16-117035
Filing Date
2016-05-03
Accepted
2016-05-03 11:46:32
Documents
7
Effectiveness Date
2016-05-03

Document Format Files

Seq Description Document Type Size
1 DEFA14A a16-9889_4defa14a.htm DEFA14A 38374
2 GRAPHIC g98894bii001.gif GRAPHIC 44227
3 GRAPHIC g98894bii002.gif GRAPHIC 36465
4 GRAPHIC g98894bgi001.gif GRAPHIC 50051
5 GRAPHIC g98894bgi002.gif GRAPHIC 102307
6 GRAPHIC g98894bgi003.gif GRAPHIC 15750
7 GRAPHIC g98894bgi004.gif GRAPHIC 4327
  Complete submission text file 0001104659-16-117035.txt   388717
Mailing Address ONE MAIN STREET SUITE 800 CAMBRIDGE MA 02142
Business Address ONE MAIN STREET SUITE 800 CAMBRIDGE MA 02142 (617) 500-7867
Aegerion Pharmaceuticals, Inc. (Filer) CIK: 0001338042 (see all company filings)

IRS No.: 202960116 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-34921 | Film No.: 161614339
SIC: 2834 Pharmaceutical Preparations